Abstract:

In recent years, the incidence of endometrial cancer (EC) has been on the rise, and the traditional pathological tissue typing cannot accurately guide the individual treatment and evaluate the prognosis of patients. The molecular typing of EC based on molecular biology technology came into being. This molecular typing has an important guiding role in postoperative chemoradiotherapy, immunotherapy and targeted therapy for EC patients. The microsatellite instability (MSI) type of EC is one of the molecular types of The Cancer Genome Atlas (TCGA). MSI type of EC has unique clinical and pathological features. In addition, it is different from other types of EC in terms of treatment and prognosis. Molecular classification has been integrated into the Guideline from European Society of Gynaecological Oncology. Recent studies have shown that the patients with MSI type of EC do not get more benefit from chemotherapy, but they can get benefits from immunotherapy. The immune therapy combined with anti-angiogenesis drugs therapy has been recommended for those patients. However, there are still some controversy on the pathological characteristics, prognosis and therapy of MSI type of EC. Several therapy protocols of the combined drugs are still under study. It is true that the individualized treatment according to the molecular classification of EC will be the research focus.

Key words: Endometrial neoplasms, DNA mismatch repair, Microsatellite instability, Immunotherapy, Prognosis